Our publications

2021 Most Impactful Papers

Dawson LP, Biswas S, Lefkovits J, Stub D, Burchill L, Evans SM, Reid C, Eccleston D. Characteristics and Quality of National Cardiac Registries: A Systematic Review. Circulation: Cardiovascular Quality and Outcomes. 2021 Sep;14(9):e007963. doi: 10.1161/CIRCOUTCOMES.121.007963.

One of the first studies to carefully review national cardiac registries, identifying key characteristics and opportunities for international collaboration of these invaluable resources.

Fernando H, Duong T, Huynh K, Noonan J, Shaw J, Duffy SJ, Nehme Z, Smith K, Myles PS, Meikle PJ, Peter K, Stub D. Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. European Heart Journal. 2021 Oct 14;42(39):4025-4036. doi: 10.1093/eurheartj/ehab557.

The first trial worldwide of non-opioid use in cardiac intervention analgesia. It provided a framework and clinical rationale for the seminal AVOID 2 ambulance trial. PhD candidate and first author Dr Hima Fernando was awarded the prestigious Ralph Reader award 2021 for this work. (4 CITES (Scopus), FWCI=1.95). Read our lay summary on the Monash Faculty of Medicine, Nursing and Health Sciences newsfeed.

Bosch J, Lonn EM, Jung H, Zhu J, Liu L, Lopez-Jaramillo P, Pais P, Xavier D, Diaz R, Dagenais G, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Held C, Peters RJG, Lewis BS, Jansky P, Yusoff K, Khunti K, Toff WD, Reid CM, Varigos J, Joseph P, Leiter LA, Yusuf S. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal. 2021 Aug 17;42(31):2995-3007. doi: 10.1093/eurheartj/ehab225.

The findings from this landmark trial have demonstrated that the poly-pill approach to blood pressure and lipid lowering improves long–term outcomes with the combined benefits of blood pressure and lipid lowering in moderate risk individuals. (Citations 5 (92nd percentile); FWCI – 3.31)

Dagan M, Dinh DT, Stehli J, Zaman S, Brennan A, Tan C, Liew D, Reid CM, Stub D, Kaye DM, Lefkovits J, Duffy SJ; Victorian Cardiac Outcomes Registry. Impact of Age and Sex on Treatment and Outcomes Following Myocardial Infarction. Journal of the American College of Cardiology. 2021 Nov 9;78(19):1934-1936. doi: 10.1016/j.jacc.2021.08.057.

This paper illustrates the importance of gender disparities in cardiovascular disease management of acute cardiac care, now the focus of major national initiatives to bridge the gap.

Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, Hay P, Rogers K, Billot L, Burke M, Chalmers J, Neal B, Patel A, Usherwood T, Webster R, Rodgers A; QUARTET Investigators. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. The Lancet. 2021 Sep 18;398(10305):1043-1052. doi: 10.1016/S0140-6736(21)01922-X.

These findings have demonstrated the safety and efficacy of a “quad-pill approach” to blood pressure lowering that produces highly significant reductions that increase the opportunity for global improvements in the prevention of cardiovascular disease. (Citations 5 (92nd percentile); FWCI = 3.31)